Devices Escape Comparative Effectiveness Study Focus With Limelight On Rx
This article was originally published in The Gray Sheet
Executive Summary
The device industry has once again received a reprieve from comparative effectiveness trial provisions as policymakers remain centered on controlling pharmaceutical costs